Michael A. Samuels

586 total citations
35 papers, 419 citations indexed

About

Michael A. Samuels is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael A. Samuels has authored 35 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Otorhinolaryngology, 15 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael A. Samuels's work include Head and Neck Cancer Studies (16 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Michael A. Samuels is often cited by papers focused on Head and Neck Cancer Studies (16 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Michael A. Samuels collaborates with scholars based in United States, Sweden and Netherlands. Michael A. Samuels's co-authors include J. James, Eugen B. Hug, Lawrence Berk, Anand Mahadevan, Lisa A. Kachnic, Anna L. Schwartz, Omar Mahmoud, Francisco Civantos, S. Samuels and Matthew C. Abramowitz and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and The Laryngoscope.

In The Last Decade

Michael A. Samuels

33 papers receiving 413 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael A. Samuels United States 12 159 141 107 93 85 35 419
Frederick M. Schnell United States 8 199 1.3× 136 1.0× 60 0.6× 192 2.1× 55 0.6× 17 481
David Skarsgard Canada 13 112 0.7× 205 1.5× 114 1.1× 107 1.2× 29 0.3× 25 450
Zhigong Wei China 10 71 0.4× 77 0.5× 73 0.7× 79 0.8× 26 0.3× 44 319
Ameish Govindarajan United States 7 123 0.8× 184 1.3× 77 0.7× 59 0.6× 16 0.2× 34 358
Ashok R. Jethwa Canada 8 149 0.9× 71 0.5× 132 1.2× 194 2.1× 35 0.4× 14 445
Anna Tomiak Canada 10 259 1.6× 184 1.3× 32 0.3× 84 0.9× 44 0.5× 17 404
Aydın Yavuz Türkiye 10 81 0.5× 130 0.9× 42 0.4× 92 1.0× 19 0.2× 33 326
Birsen Yücel Türkiye 11 205 1.3× 123 0.9× 57 0.5× 64 0.7× 11 0.1× 53 362
Judi van Diessen Netherlands 7 123 0.8× 287 2.0× 82 0.8× 31 0.3× 34 0.4× 14 460
D. Riesenbeck Germany 10 269 1.7× 583 4.1× 288 2.7× 90 1.0× 52 0.6× 33 751

Countries citing papers authored by Michael A. Samuels

Since Specialization
Citations

This map shows the geographic impact of Michael A. Samuels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Samuels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Samuels more than expected).

Fields of papers citing papers by Michael A. Samuels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Samuels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Samuels. The network helps show where Michael A. Samuels may publish in the future.

Co-authorship network of co-authors of Michael A. Samuels

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Samuels. A scholar is included among the top collaborators of Michael A. Samuels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Samuels. Michael A. Samuels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Samuels, Michael A., Voichita Bar‐Ad, Juergen Dunst, et al.. (2023). A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors. International Journal of Radiation Oncology*Biology*Physics. 118(3). 743–756. 36 indexed citations
2.
Rich, Benjamin, Zoukaa Sargi, Deukwoo Kwon, et al.. (2023). ED visits, hospital admissions and treatment breaks in head/neck cancer patients undergoing radiotherapy. Frontiers in Oncology. 13. 1147474–1147474. 2 indexed citations
3.
4.
Smith, Drew H., Michael A. Samuels, Sapna K. Deo, et al.. (2021). Current salivary biomarkers for detection of human papilloma virus‐induced oropharyngeal squamous cell carcinoma. Head & Neck. 43(11). 3618–3630. 7 indexed citations
5.
Padgett, Kyle R., et al.. (2021). CBCT-Based Adaptive Assessment Workflow for Intensity Modulated Proton Therapy for Head and Neck Cancer. International Journal of Particle Therapy. 7(4). 29–41. 14 indexed citations
6.
Bossart, Elizabeth, Kyle R. Padgett, Tejan Diwanji, et al.. (2021). Knowledge-Based Planning for Robustly Optimized Intensity-Modulated Proton Therapy of Head and Neck Cancer Patients. Frontiers in Oncology. 11. 737901–737901. 8 indexed citations
7.
Civantos, Francisco, Jason M. Leibowitz, David Arnold, et al.. (2020). Ethical surgical triage of patients with head and neck cancer during the COVID‐19 pandemic. Head & Neck. 42(7). 1423–1447. 19 indexed citations
8.
Lo, Kaming, et al.. (2019). Complications and toxicity of re-irradiation following total laryngectomy for laryngeal cancer. Journal of Radiation Oncology. 8(4). 369–377. 1 indexed citations
9.
Perlow, Haley K., Stephen J. Ramey, Deukwoo Kwon, et al.. (2018). Assessment of Oropharyngeal and Laryngeal Cancer Treatment Delay in a Private and Safety Net Hospital System. Otolaryngology. 159(3). 484–493. 13 indexed citations
10.
11.
Mahmoud, Omar, et al.. (2017). Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus. Head & Neck. 40(4). 710–721. 40 indexed citations
12.
Diaz, Dayssy A., et al.. (2015). Head and neck second primary cancer rates in the human papillomavirus era: A population‐based analysis. Head & Neck. 38(S1). E873–83. 20 indexed citations
13.
Saigal, Kunal, Edgardo S. Santos, Khaled Tolba, et al.. (2014). Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology. 4. 165–165. 7 indexed citations
14.
Lilenbaum, Rogério, Michael A. Samuels, Xiaofei Wang, et al.. (2014). A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). Journal of Thoracic Oncology. 10(1). 143–147. 43 indexed citations
15.
Lilenbaum, Rogério, et al.. (2010). Phase II Trial of Combined Modality Therapy with Myeloid Growth Factor Support in Patients with Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 837–840. 5 indexed citations
16.
Ryu, Byungwoo, et al.. (2008). Id1 delays senescence of primary human melanocytes. Molecular Carcinogenesis. 47(9). 653–659. 13 indexed citations
17.
Berk, Lawrence, J. James, Anna L. Schwartz, et al.. (2008). A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Supportive Care in Cancer. 16(10). 1179–1188. 91 indexed citations
18.
Raez, Luis E., Michael A. Samuels, & Rogerio Lilenbaum. (2005). Combined modality therapy for limited-disease small cell lung cancer. Current Treatment Options in Oncology. 6(1). 69–74. 7 indexed citations
19.
Samuels, Michael A., et al.. (2003). Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design. Seminars in Oncology. 30(6 Suppl 18). 94–95. 4 indexed citations
20.
Samuels, Michael A., et al.. (2003). Ongoing prospective multi-center safety study of subcutaneous cytoprotectant amifostine. International Journal of Radiation Oncology*Biology*Physics. 57(2). S224–S224.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frederick M. Schnell Breakdown of academic impact, for papers by David Skarsgard Breakdown of academic impact, for papers by Zhigong Wei Breakdown of academic impact, for papers by Ameish Govindarajan Breakdown of academic impact, for papers by Ashok R. Jethwa Breakdown of academic impact, for papers by Anna Tomiak Breakdown of academic impact, for papers by Aydın Yavuz Breakdown of academic impact, for papers by Birsen Yücel Breakdown of academic impact, for papers by Judi van Diessen Breakdown of academic impact, for papers by D. Riesenbeck
Rankless by CCL
2026